Search
Dr. Wolchinsky Receives Pioneer Award | Boehringer Ingelheim US
Read more about Dr. Steven Wolchinsky receiving the first Vetmedin® (pimobendan) Cardiology Pioneer award, for his work and commitment to animal health.
Romy's Third-generation Japanese American Journey
Romy's Third-generation Japanese American Journey
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Interview with Norbert Kraut: How cancer drives us forward
Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
Fremont, CA site
Fremont, CA site
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Management Rotation | Academic Programs
Management Rotation Program
First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US
Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.
Social Impact | COVID-19 | Boehringer Ingelheim US
Click to find out more on how Boehringer Ingelheim (BI) is standing together with our communities to support the fight against the COVID-19 pandemic.
Obesity
Obesity
Patient Assistance Program
BI Cares Patient Assistance Program Error
Animal Health: Our Responsibility
BI's commitment to animal health is reflected in our more than 100 years of successful company history. It is also at the core of sustainability.
Cancer
Cancer
Boehringer Ingelheim Launches External Innovation Hub in China
Boehringer Ingelheim Launches External Innovation Hub in China
Management Rotation
Click here to read testimonies from our employees who enrolled in our management rotation program.
Boehringer Ingelheim Fremont, Inc.
Fremont, California, is the home of Boehringer Ingelheim’s rapidly growing US Biopharmaceuticals Business Unit
Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US
Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.
Coliform Mastitis: the facts to know | Boehringer Ingelheim US
Click here to learn more about different management practices that can help you to improve your dairy herd's bottom line and productivity.
Our Biotherapeutic Technology Partnering Interests
Our Biotherapeutic Technology Partnering Interests
The NCD Initiative | Infographic
Animal Health | COVID-19 | Boehringer Ingelheim US
Click here to read more on how the COVID-19 pandemic has impacted the daily lives of veterinarians, livestock producers and others.
Confronting health disparities in clinical trials
As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.